R-6890 is an opiate compound with analgesic potencies.

Orphine is an opioid compound. Orphine can enhance the antinociceptive effects in mice that are mitigated by Naloxone and a linker

N-Phenethylnoroxymorphone is an opioid compound. N-Phenethylnoroxymorphone enhances morphine-induced analgesia in rats. N-Phenethylnoroxymorphone can be used for research on neurological diseases.

Norcarfentanil hydrochloride is an opioid and is a metabolite of Carfentanil.

Nor-6α-Oxycodol is structurally similar to known opioids and is a metabolite of Oxycodone.

Naltrindole 5′-isothiocyanate (5'-NTII) is a non-selective delta opioid receptor antagonist that can antagonize the analgesic effects induced by DSLET without affecting the analgesic effects induced by DPDPE.

Methylketobemidone is structurally similar to known opioids.

Meta-fluoro 4-ANBP (m-Fluoro 4-ANBP) is structurally similar to known opioids.

LPK-26 hydrochloride is a selective kappa-opioid receptor agonist with a Ki of 0.68 nM. LPK-26 exhibits potent antinociceptive effects with low physical dependence potential and can be utilized in relevant research.

Homprenorphine is an opioid alkaloid derivative, structurally related to Cyprenorphine.

Fluorphine is an analogue of Brorphine and can bind to μ-opioid receptor (MOR) (Ki: 12.5 nM). Fluorphine has GTPγS binding (EC50: 75 nM) and βarrestin 2 recruitment (EC50: 377 nM) activity. Fluorphine induces respiratory depressant effects.

FEKAP is a brain-penetrant and selective kappa opioid receptor (KOR) agonist (Ki = 0.43 nM) which isotope labeled form exhibits excellent imaging properties. 11C-FEKAP can be utilized as a radiotracer for imaging KOR.

Dipyanone hydrochloride is structurally similar to known opioids.

Difelikefalin (CR-845; FE-202845) acetate is a peripherally restricted and selective agonist of kappa opioid receptor (KOR). Difelikefalin acetate produces anti-inflammatory effects and has the potential in modulating pruritus in conditions such as chronic kidney disease.

DH-1-106 is a MOR partial agonist. DH-1-106 can be used in the study of analgesia.

DBPR116 is a prodrug of BPRMU191 with blood-brain barrier penetration capability. DBPR116 significantly improves the delivery of centrally targeted drugs. In combination with the antagonist Naltrexone, DBPR116 demonstrated superior safety and analgesic efficacy compared to morphine in various in vivo pharmacological studies, including thermal pain models, cancer pain models, constipation, sedation, psychological dependence, heart rate, and respiratory frequency. As a prodrug strategy for peripheral administration, DBPR116 effectively alleviates pain while reducing adverse effects, showing potential as a safer opioid analgesic.

Cyprodime is a selective μ opioid receptor (MOR) antagonist with Kis of 5.4, 244.6, and 2187 nM for μ, δ, and κ, respectively.

Chlorphine is a neuroactive halogenated opioid analog.

Cebranopadol hemicitrate is an analgesic NOP and opioid receptor agonist with Kis/EC50s of 0.9 nM/13 nM, 0.7 nM/1.2 nM, 2.6 nM/17 nM, 18 nM/110 nM for human NOP, MOP, KOP and delta-opioid peptide (DOP) receptor, respectively. Cebranopadol hemicitrate can be used for acute and chronic pain study.

BU72 is a highly potent and long-acting agonist of μ and κ opioid receptors, and also has a partial agonist effect on δ opioid receptors (EC50 values are 0.054, 0.033, and 0.58 nM, respectively). BU72 has a strong and long-lasting analgesic effect, which is mainly mediated by μ opioid receptors. BU72 has a long-lasting activity and can partially reverse the analgesic effect of morphine. BU72 can be used in the study of opioid dependence.

Bromadoline is a utopioid with antinociceptive activity in rodents.

Bromadol is an opioid.

BPRMU191 is a μ-opioid receptor (MOR) modulator that converts small-molecule morphinan antagonists into G protein-biased MOR agonists, thereby inducing MOR-dependent activation and analgesic effects. Co-administration of BPRMU191 with morphinan antagonists provides analgesia while reducing side effects such as gastrointestinal dysfunction, antinociceptive tolerance, and dependency-related adverse effects. BPRMU191, in combination with morphinan antagonists, offers a potential strategy for studying severe pain management and G protein-coupled receptor modulation.

BNTX (7-Benzylidenenaltrexone) maleate is a δ1-opioid receptor antagonist with the Kis of 0.1, 10.8, 13.3, and 58.6 nM for δ1, δ2-, μ-, and κ-opioid receptor, respectively. BNTX maleate shows antinociceptive activity.

Bipiperidinyl 4-ANPP is structurally similar to known opioids.

AZ 12488024 (AZD7268) is a SNC80.

AP-238 is a a new synthetic opioid (NSO), and acts as an agonist for μ-opioid receptor (MOR) with an EC50 of 248 nM. AP-238 exhibits analgesic activity.

Alvimopan metabolite hydrochloride is a peripherally restricted Opioid Receptor antagonist that inhibits the amplitude of electrically evoked contractions and spontaneous mechanical activity in guinea pig ileum.

Allyphenyline oxalate (compound 9) can enhance the analgesic effect of Morphine. The pKi values ​​of Allyphenyline for α2A, α2B and α2C are 7.24, 6.47 and 7.07, respectively.

AH-8533 is a opioid agent.